Risk Factors Update Summary
- Increased scrutiny on data privacy laws requires significant resources, including financial and time-related, to comply.
- Accumulated deficit decreased from $5.4 billion to $3.3 billion, a significant improvement.
- Transitioning devices to FDA cleared status may increase costs and impact profitability.
- Operating expenses expected to either remain consistent or decline in 2024 compared to 2023.
- Cybersecurity risks are constantly evolving, with sophisticated threats and potential interruptions in operations.
- Losses may continue, requiring additional capital for strategic investments and acquisitions.
- Increased focus on global surveillance programs and analytic services in the Biosecurity business.
- Expansion into the European Union with new companies like BiomEdit, Motif FoodWorks, and others.
- Potential limitations in scaling up biosecurity efforts due to expense or material unavailability.
- Increased focus on AI technology development with a strategic partnership with Google Cloud.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1830214&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.